XTL Biopharma (XTLB) Receives European Patent Related to hCDR1

September 7, 2016 8:33 AM EDT
Get Alerts XTLB Hot Sheet
Trade XTLB Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB) announced the European Patent Office (EPO) has granted a patent for the Company's lupus drug candidate, hCDR1. Patent EP1594434 entitled, "Parenteral Formulations of Peptides for the Treatment of Systemic Lupus Erythematosus," claims formulations of hCDR1 and use of these pharmaceutical compositions in the treatment of systemic lupus erythematosus (SLE) that may be validated in the EPO's 27 member countries.

"This important patent in Europe augments the robust intellectual property position we are building globally. hCDR1 has been granted patents in markets including the U.S., Canada, Australia, Korea, Japan, India, and China. We continue to strengthen our intellectual property portfolio through new patent filings on the most recent inventions like the patent just filed in the U.S. for a different dosing regimen of hCDR1," stated Josh Levine, CEO of XTL. "Europe is one of the largest markets in the world for SLE, with few effective treatment options available. Through our upcoming Phase 2 trial, we look forward to developing hCDR1 as a potential treatment to serve this unmet need."

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment